Acrivon Therapeutics, Inc. Common StockACRVNASDAQ
Loading
Operating Expenses Over TimeStrong
Percentile Rank80
3Y CAGR+37.1%
5Y CAGR+92.7%
Year-over-Year Change
Expenses from normal business operations (SG&A, R&D, etc.)
3Y CAGR
+37.1%/yr
Annual compound
5Y CAGR
+92.7%/yr
Recent deceleration
Percentile
P80
Within normal range
vs 5Y Ago
26.6x
Strong expansion
Streak
1 yr
Consecutive declineStrong
| Period | Value | YoY Change |
|---|---|---|
| 2025 | $84.11M | -4.6% |
| 2024 | $88.19M | +32.2% |
| 2023 | $66.70M | +104.2% |
| 2022 | $32.66M | +101.8% |
| 2021 | $16.18M | +410.9% |
| 2020 | $3.17M | - |